Anna A Lushnikova, Anastasia V Onyan, Anna A Rudakova, Alexandr V Kostarev, Kseniya V Kozhikhova, Sergey M Andreev, Natalya I Moiseeva, Mariya A Baryshnikova
{"title":"Overcoming of doxorubicin resistance in breast cancer cells by cationic peptides","authors":"Anna A Lushnikova, Anastasia V Onyan, Anna A Rudakova, Alexandr V Kostarev, Kseniya V Kozhikhova, Sergey M Andreev, Natalya I Moiseeva, Mariya A Baryshnikova","doi":"10.15406/jcpcr.2019.10.00405","DOIUrl":null,"url":null,"abstract":"Drug resistance in tumor cells is one of the obstacles for effective cancer chemotherapy. Novel strategies for therapy of multi-drug resistant tumors include the combinations of doxorubicin with microRNA.1 Metformin2 and other prodrugs. Various molecular constructions are used to codeliver doxorubicin +metformin followed by release metformin to enhance Dox cytotoxicity through attenuating hypoxic stress and inhibition of HIF1α/Pgp expression. Small molecular inhibitors of oncoproteins and essential cell pathways are considered now as promising therapeutic agents.","PeriodicalId":15185,"journal":{"name":"Journal of Cancer Prevention & Current Research","volume":"49 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention & Current Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/jcpcr.2019.10.00405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Drug resistance in tumor cells is one of the obstacles for effective cancer chemotherapy. Novel strategies for therapy of multi-drug resistant tumors include the combinations of doxorubicin with microRNA.1 Metformin2 and other prodrugs. Various molecular constructions are used to codeliver doxorubicin +metformin followed by release metformin to enhance Dox cytotoxicity through attenuating hypoxic stress and inhibition of HIF1α/Pgp expression. Small molecular inhibitors of oncoproteins and essential cell pathways are considered now as promising therapeutic agents.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
